Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2025 | $14.00 | Outperform | Oppenheimer |
4/4/2025 | Buy | Berenberg | |
11/18/2024 | $15.00 → $10.00 | Buy | H.C. Wainwright |
4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
11/1/2022 | $18.00 | Buy | Loop Capital |
11/30/2021 | $25.00 | Buy | Maxim Group |
11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
S-3ASR - ATAI Life Sciences N.V. (0001840904) (Filer)
DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00
Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy
H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the potential to enhance the clinical response beyond what is observed with a single administrationFindings will be used alongside data from Beckley Psytech's Phase 2b study of BPL-003 and the soon to be reported Phase 2b open-label extension study to inform the Phase 3 clinical program NEW YORK and AMST
NEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that it has been awarded a multi-year, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The UG3/UH3 grant will fund the optimization and early-stage development of atai's novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder (OUD). "This grant award underscores atai's and NIDA's shared dedi
NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences. Details of the Company's participation are as follows: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Friday, September 5th at 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Format: Fireside ChatDate and Time: Monday, September 8th at 11:30 a.m. ETLocatio
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t
Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th